




January 2019

Volume 24 Number 1
pp. 1–360



Cover Story

The lead story in this issue of Drug Discovery Today is by William F. Salminen, Marc E. Wiles and Ruth E. Stevens of Camargo Pharmaceutical Services, Cincinnati, OH, USA and is entitled: "Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway." The authors outline how new drug applications (NDAs) using the FDA 505(b)(2) regulatory pathway can streamline and reduce nonclinical drug development requirements while potentially maintaining marketing exclusivity.

DRUG DISCOVERY TODAY

EDITORIAL

- 1 Renovation as innovation: is repurposing the future of drug discovery research?**

Arthur Neuberger, Nektarios Oraopoulos and Donald L. Drakeman

PERSPECTIVE

FEATURE

- 4 The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan**
Shunsuke Matsushita, Keisuke Tachibana and Masuo Kondoh
- 9 Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management**
Zhining Wen, Yu Liang, Yingyi Hao, Brian Delavan, Ruili Huang, Mike Mikailov, Weida Tong, Menglong Li and Zhichao Liu
- 16 How soon will digital endpoints become a cornerstone for future drug development?**
Philip Boehme, Arne Hansen, Ronenn Roubenoff, Joseph Scheeren, Maximilian Herrmann, Thomas Mondritzki, Jan Ehlers and Hubert Truebel
- 20 Patent term restoration for top-selling drugs in the United States**
Reed F. Beall, Jonathan J. Darrow and Aaron S. Kesselheim
- 26 Translational *in vitro* research: integrating 3D drug discovery and development processes into the drug development pipeline**
Jens M. Kelm, Madhu Lal-Nag, Gurusingham Sitta Sittampalam and Marc Ferrer
- 31 Turning straw into gold: building robustness into gene signature inference**
Wilson Wen Bin Goh and Limsoon Wong
- 37 A well-tolerated and rapidly acting thiopurine for IBD?**
Timothy H.J. Florin, John D. Wright, Siddharth D. Jambhrunkar, Michael G. Henman and Amirali Popat
- 42 Considerations for implementing an informatics system to support biologics drug discovery**
Andrew P. LeBeau

REVIEWS

FOUNDATION

- 46 Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway**
William F. Salminen, Marc E. Wiles and Ruth E. Stevens
- 57 Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review**
Eline van Overbeeke, Chiara Whichello, Rosanne Janssens, Jorien Veldwijk, Irina Cleemput, Steven Simoens, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Esther de Bekker-Grob, and Isabelle Huys